Financial Performance - For the three months ended March 31, 2021, the group achieved a consolidated revenue of RMB 124,407,625, representing an increase of 81.55% compared to RMB 68,523,880 for the same period last year[6] - The consolidated gross profit for the same period was RMB 13,722,640, reflecting a significant increase of 253.42% from RMB 3,882,817 in the previous year[6] - The loss attributable to equity holders of the company was RMB 165,625, a decrease of 97.04% compared to a loss of RMB 5,591,384 in the same period last year[6] - The basic loss per share for the period was RMB 0.009, compared to RMB 0.295 for the same period last year[6] - The group reported a pre-tax loss of RMB 1,493,248, significantly improved from a loss of RMB 5,945,839 in the previous year[7] - The total sales cost for the period was RMB 110,684,985, compared to RMB 64,641,063 in the previous year[7] - The research and development and administrative expenses amounted to RMB 7,455,064, compared to RMB 5,568,630 in the previous year[7] - The comprehensive gross profit for the same period was RMB 13,722,640, which is a 253.42% increase from RMB 3,882,817 year-on-year, resulting in a gross margin of 11.03%, up by 5.36% from 5.67%[18] Revenue Sources - The revenue from fertilizer products was RMB 124,379,590, up from RMB 68,473,752 in the previous year, while revenue from elderly care and health services was RMB 28,035, down from RMB 50,128[9] Dividends and Shareholder Returns - The group did not recommend the payment of any dividend for the three months ended March 31, 2021[6] - The company does not recommend the payment of an interim dividend for the three months ended March 31, 2021, consistent with no dividend declared in the same period last year[15] Business Strategy and Development - The company is actively expanding its biocomposite fertilizer business and elderly care services, focusing on the integration of medical and elderly care services[17] - The company plans to adopt new marketing strategies to promote its new series of fertilizers, aiming for sustainable development in the biocomposite fertilizer sector[22] - The company is experiencing slow development in its EEG detection business but is actively seeking new partnerships to enhance growth in this area[23] - The company is committed to improving its elderly care services by developing or investing in high-end elderly care institutions and enhancing its professional capabilities in elderly care[23] - The company is focused on biomedical engineering and aims to enhance its market presence[38] - The company plans to continue its research and development efforts in new products and technologies[38] - The company is exploring potential market expansions to increase its competitive edge[38] - The company emphasizes the importance of strategic partnerships and collaborations in its growth strategy[38] - The company aims to improve operational efficiency through innovative practices[38] - The company is dedicated to maintaining high standards of corporate governance[38] - The company is focused on enhancing shareholder value through sustainable growth initiatives[38] Financial Liabilities and Governance - The company faces a contingent liability of RMB 3,000,000 related to bank loans secured by its subsidiaries as of March 31, 2021, compared to zero as of December 31, 2020[19] - The company’s treasury policy involves bank borrowings settled in RMB, with cash balances deposited in licensed banks in China[21] - The company has committed to adhering to the corporate governance principles outlined in the GEM Listing Rules[37] - The company did not establish any arrangements allowing directors or supervisors to profit from purchasing company shares during the review period[26] - The company has not approved any new share option plans during the period ending March 31, 2021[34] - There were no management contracts signed for overall business or any major business during the period ending March 31, 2021[35] - The company has not disclosed any competitive interests or conflicts of interest involving its directors or management during the review period[32] Shareholder Information - As of March 31, 2021, major shareholders include Tianjin TEDA International Entrepreneurship Center with 182,500,000 shares (9.63%), Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%), and Shandong Zhinong Fertilizer Co., Ltd. with 180,000,000 shares (9.50%)[27] Audit and Reporting - The company’s audit committee, consisting of three independent non-executive directors, reviewed the financial results for the first quarter ending March 31, 2021[33] - The report will be available for at least seven days on the GEM website and the company's website[38] - The company is committed to transparency and will publish its announcements on its official platforms[38]

Company Overview - The registered capital of Tianjin TEDA Biomedical Engineering Company Limited is RMB 189.045 million[6]. - Tianjin TEDA Biomedical Engineering Company Limited was officially listed on the GEM of the Hong Kong Stock Exchange on June 18, 2002[6]. - The company operates in two main business areas: bio-composite fertilizers and elderly care services, focusing on the needs of disabled and cognitively impaired individuals[6]. - The group structure includes multiple subsidiaries dedicated to various aspects of biomedical engineering and elderly care services[8]. Financial Performance - Revenue for 2020 was RMB 369,355 thousand, showing a slight increase from RMB 358,752 thousand in 2019[13]. - Gross profit for 2020 was RMB 40,392 thousand, with a gross margin of 10.94%, up from 9.75% in 2019[13]. - The company reported a loss attributable to shareholders of RMB 47,998 thousand in 2020, an improvement from a loss of RMB 84,622 thousand in 2019[13]. - Total assets as of December 31, 2020, were RMB 392,919 thousand, compared to RMB 361,913 thousand in 2019[13]. - Total liabilities increased to RMB 237,775 thousand in 2020 from RMB 156,406 thousand in 2019[13]. - The company's revenue for the year ended December 31, 2020, was RMB 369,355,184, representing a year-on-year increase of 2.96%[20]. - The comprehensive gross profit margin increased by 11.79% to RMB 40,391,685 compared to the previous year[20]. - The loss attributable to shareholders was RMB 47,998,435, with a loss per share of RMB 2.53, a decrease of 43.40% from the previous year's loss per share of RMB 4.47[20]. Business Operations - The bio-composite fertilizer business includes a range of products aimed at promoting balanced growth of various crops[6]. - The company has completed acquisitions to utilize exclusive EEG quantitative detection technology for diagnosing neurological and psychological disorders[6]. - The company is expanding its elderly care services across the country, integrating resources and providing management and consulting services[6]. - The company is also involved in health food research and development through its subsidiary Tianjin Alpha Health Products Co., Ltd.[8]. - The company has initiated an intelligent upgrade of manufacturing processes, enhancing production efficiency and reducing energy consumption[16]. - The company plans to expand its rental business for rehabilitation aids, capitalizing on government policies promoting this sector[16]. - The company aims to enhance its service quality in elderly care through standardized service systems and operational management[16]. - The company is focusing on product structure adjustments and manufacturing process upgrades to promote sustainable development in its compound fertilizer business[26]. - The company aims to improve the efficiency of fertilizer use and promote the development of specialized fertilizers to meet changing market demands[21]. Environmental and Social Responsibility - The company has established comprehensive waste management practices, achieving full utilization of solid waste generated[141]. - The company adheres to strict emission standards, including air quality standards of ≤20 mg/m³ for particulate matter and ≤100 mg/m³ for SO2[143]. - The company has eliminated hazardous waste management status due to low generation of hazardous waste and internal recycling practices[143]. - The company integrates environmental, social, and governance (ESG) responsibilities into its core business operations[137]. - The company has implemented a corporate social responsibility strategy focusing on employee rights, consumer care, environmental protection, and social responsibility[137]. Governance and Compliance - The company emphasizes the importance of accurate and complete information in its financial reporting and corporate governance[2]. - The board of directors includes three executive directors, three non-executive directors, and two independent non-executive directors, maintaining a balanced governance structure[66]. - The company has a strong governance structure with experienced independent directors, enhancing its oversight capabilities[84]. - The audit committee held six meetings during the fiscal year to review the financial reporting procedures and the effectiveness of internal controls[94]. - The company has complied with all provisions of the corporate governance code except for one specific provision during the review year[100]. - The company emphasizes high transparency and timely disclosure of relevant information to shareholders through various formal communication channels[136]. Employee Management - The total number of employees is 390, with 75% male and 25% female[190]. - Employee turnover rate is 14.9%, with a breakdown of 10.5% for male and 4.4% for female employees[193]. - The company emphasizes occupational health and safety, providing safety training and regular health check-ups for employees[197]. - The total training hours for the year amounted to 1,736 hours, with 103 employees participating in various training programs[198]. - The average training hours per employee was 4.5 hours, with a training participation rate of 26%[199]. Market and Product Development - The fertilizer industry is undergoing unprecedented innovation, with new formulations and technologies emerging, presenting opportunities for integration and development[21]. - The company has successfully developed eight new series of fertilizers, including water-soluble fertilizers and microbial fertilizers, to enhance product targeting and effectiveness[48]. - The company plans to adopt new marketing strategies to actively promote its new fertilizer series, aiming for sustainable and healthy development of its compound fertilizer business[48]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic investments and partnerships[70].

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） （股份代號：8189） 2020 第三季度報告 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳 的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關 天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本報 ...

Financial Performance - For the six months ended June 30, 2020, the group achieved a consolidated revenue of RMB 165,271,920, a decrease of 17.68% compared to RMB 200,755,549 for the same period last year[5] - The consolidated gross profit for the same period was RMB 14,562,341, down 42.78% from RMB 25,449,134 year-on-year[5] - The loss attributable to equity holders of the company was RMB 5,266,120, a reduction of 22.95% compared to a loss of RMB 6,835,079 in the previous year[5] - The company reported a basic loss per share of RMB 0.278, compared to RMB 0.361 for the same period last year[5] - Revenue from fertilizer products for the six months ended June 30, 2020, was RMB 165,061,211, a decrease from RMB 197,750,732 in the same period of 2019, reflecting a decline of approximately 16.6%[10] - The compound fertilizer business experienced a revenue decline of 16.93% year-on-year due to the impact of COVID-19 and adverse weather conditions[32] - The group's sales and distribution costs for the six months ended June 30, 2020, were RMB 9,339,918, a decrease of 3.07% compared to RMB 9,636,064 for the same period in 2019[33] - Research and administrative expenses for the same period were RMB 13,713,407, down 32.93% from RMB 20,445,160 in 2019[34] Assets and Liabilities - The total assets of the company as of June 30, 2020, amounted to RMB 394,340,491, compared to RMB 361,912,836 as of December 31, 2019[8] - Current liabilities totaled RMB 130,009,335, a decrease from RMB 156,405,901 at the end of the previous year[8] - The net asset value of the company was RMB 264,331,156, an increase from RMB 205,506,935 at the end of the previous year[8] - The net trade receivables as of June 30, 2020, amounted to RMB 68,115,734, up from RMB 60,340,201 as of December 31, 2019, indicating a growth in receivables[22] - Other receivables, net of bad debt provision, increased to RMB 29,769,410 as of June 30, 2020, compared to RMB 12,910,478 as of December 31, 2019[23] - Trade payables totaled RMB 22,365,796 as of June 30, 2020, up from RMB 19,283,679 as of December 31, 2019[24] - Other payables decreased to RMB 33,949,769 as of June 30, 2020, from RMB 38,262,444 as of December 31, 2019[25] Cash Flow and Financing - The company reported a net cash outflow from operating activities of RMB (10,036,490) for the six months ended June 30, 2020, compared to RMB (24,821,594) in the same period of 2019, indicating a significant improvement[9] - The financing cash outflow for the six months ended June 30, 2020, was RMB (2,200,000), slightly improved from RMB (2,500,000) in the same period of 2019[9] - The company’s cash and bank balances decreased to RMB 11,769,699 as of June 30, 2020, from RMB 15,288,638 as of June 30, 2019[9] - The company’s interest expense on bank loans for the six months ended June 30, 2020, was RMB 663,362, down from RMB 1,685,338 in the same period of 2019, showing a reduction in financing costs[11] - Financing costs decreased by 60.64% to RMB 663,362 from RMB 1,685,338 in the previous year[35] Dividends and Shareholder Information - The company did not recommend the payment of any dividend for the six months ended June 30, 2020[5] - The company did not recommend an interim dividend for the six months ended June 30, 2020, compared to no dividend in the same period of 2019[28] - Major shareholders as of June 30, 2020, include Tianjin TEDA International Venture Capital Center with 182,500,000 shares (9.63%), Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%), and Shandong Zhinong Fertilizer Co., Ltd. with 180,000,000 shares (9.50%) [46] Corporate Governance and Compliance - The company did not approve any new share option schemes during the period ended June 30, 2020 [54] - The company has not entered into any management or administrative contracts for its overall business during the first half of 2020 [55] - The company has adopted a code of conduct for securities trading that is not less stringent than the GEM Listing Rules [56] - No shares were repurchased by the company or its subsidiaries during the review period [57] - The company has complied with all provisions of the Corporate Governance Code except for the requirement that the roles of the Chairman and CEO should be separate [58] - The company is in the process of selecting candidates for the CEO position to enhance corporate governance transparency and independence [59] Future Plans and Strategic Focus - The company is focusing on the development of assistive device rental services as a key profit growth point in the elderly care business[31] - The company is actively seeking new partnerships to expand its EEG testing business despite slow growth due to COVID-19[31] - The company is upgrading its fertilizer production equipment and processes to develop differentiated, high-quality fertilizers to meet agricultural production needs[30] - The group plans to focus on the development of organic fertilizers, which are expected to enhance resource utilization and optimize the environment[41] - The group aims to develop its own high-end elderly care institutions in the future while continuing to provide management consulting services to other elderly care facilities[42] - The quantitative EEG detection technology is expected to become a profit growth point for the company, despite its slow development due to various factors[42] Contingent Liabilities - The group has a contingent liability of RMB 10,893,750 related to bank loans secured by its subsidiaries, down from RMB 15,000,000 at the end of 2019[39]

Financial Performance - For the three months ended March 31, 2020, the group achieved a consolidated revenue of RMB 68,523,880, a decrease of 21.82% compared to RMB 87,652,324 for the same period last year[4] - The consolidated gross profit for the same period was RMB 3,882,817, representing a decrease of 64.65% from RMB 10,982,595 year-on-year[4] - The loss attributable to equity holders of the company was RMB 5,591,384, an increase of 74.22% compared to a loss of RMB 3,209,427 in the previous year, with a loss per share of RMB 0.295 compared to RMB 0.169 last year[4] - The group reported a pre-tax loss of RMB 5,945,839 for the three months ended March 31, 2020, compared to a pre-tax loss of RMB 3,122,862 in the same period last year[5] - Research and administrative expenses for the period were RMB 5,568,630, down from RMB 9,099,684 in the previous year[5] - Financing costs decreased to RMB 418,031 from RMB 928,062 year-on-year[5] - The group did not incur any income tax expenses for the three months ended March 31, 2020, compared to RMB 62,248 in the previous year[9] Dividend Policy - The company did not recommend the payment of a dividend for the three months ended March 31, 2020[4] - The company does not recommend the payment of an interim dividend for the three months ended March 31, 2020, consistent with no dividend in the first quarter of 2019[13] Business Operations - The company is actively expanding its elderly care services, focusing on management consulting for other elderly care institutions and properties, and plans to develop its own high-end elderly care facilities in the future[21] - The company is also working on enhancing its quantitative EEG detection business, which has broad application prospects despite slow development due to various factors[21] - The company has taken measures to resume production and operations in response to the COVID-19 pandemic, with fertilizer sales gradually increasing since February 2020[20] - The company is focusing on green development in the fertilizer industry, aiming to adjust its product structure and reduce resource consumption while promoting sustainable development[20] Shareholder Information - As of March 31, 2020, Ms. Sun Li holds 300,000,000 shares, representing 15.83% of the issued share capital[23] - Major shareholders include Tianjin TEDA International Entrepreneurship Center with 182,500,000 shares (9.63%), Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%), and Shandong Zhinong Fertilizer Co., Ltd. with 180,000,000 shares (9.50%)[29] - No other individuals, apart from those disclosed, are known to hold 5% or more of the issued share capital[30] Corporate Governance - The company has confirmed that there are no competitive interests or conflicts of interest involving its directors or management[34] - The audit committee consists of three independent non-executive directors, with Mr. Li Xudong serving as the chairman due to his professional accounting qualifications and auditing experience[35] - The company has adhered to the corporate governance principles outlined in the GEM Listing Rules, emphasizing effective board establishment, sound internal controls, and transparency to all shareholders during the review period[39] Legal and Compliance - The arbitration process regarding the profit guarantee with SJK is ongoing, initiated due to non-compliance with the agreement terms[33] - The company has not established any arrangements that would allow directors or their family members to profit from purchasing company shares during the review period[25] - No new share option plans were approved during the period ending March 31, 2020[36] - There were no management contracts signed for overall business or any major business administrative work during the period ending March 31, 2020[37] - The company did not redeem any of its shares during the review period, nor did it or any of its subsidiaries purchase, sell, or redeem any shares of the company during the period ending March 31, 2020[38] Financial Guarantees - The company has provided guarantees for bank loans of its subsidiaries, with contingent liabilities amounting to RMB 11,392,158.37 as of March 31, 2020, down from RMB 15,000,000 at the end of 2019[17] Currency Risk - The company faces minimal foreign currency risk as all sales and payments to suppliers are settled in RMB[18]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） （股份代號：8189） 2019 二零一九年年報 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的市場。有意投資 的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險，同 時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關天津泰達生物醫學工程股份 有限公司（「本公司」）的資料；本公司董事願就本報告的資料共同及個別地承擔全部責任。本公司各董事在作出一 ...

Financial Performance - For the nine months ended September 30, 2019, the group achieved a consolidated revenue of RMB 284,497,765, representing a year-on-year increase of 5.76% compared to RMB 268,996,084 for the same period in 2018[6]. - The consolidated gross profit for the same period was RMB 30,848,000, which reflects a year-on-year decrease of 19.07% from RMB 38,118,816 in 2018[6]. - The loss attributable to equity holders of the company for the nine months ended September 30, 2019, was RMB 14,158,779, compared to a loss of RMB 59,054,824 for the same period in 2018, resulting in a basic loss per share of RMB 0.75[6]. - The group incurred a pre-tax loss of RMB 13,584,656 for the nine months ended September 30, 2019, compared to a pre-tax loss of RMB 56,712,046 in the same period of 2018[7]. - The company reported a net loss of RMB 13,548,651 for the nine months ended September 30, 2019, compared to a net loss of RMB 56,894,106 in 2018[7]. - The income tax expense for the nine months ended September 30, 2019, was RMB (36) compared to RMB 182 for the same period in 2018[10]. - For the nine months ended September 30, 2019, the total operating revenue was RMB 284,497,765, an increase of 5.76% compared to RMB 268,996,084 for the same period in 2018[18]. - The consolidated gross profit for the same period was RMB 30,848,000, a decrease of 19.07% from RMB 38,118,816 in 2018, resulting in a gross profit margin of 10.84%, down 3.33% from 14.17%[18]. - Basic loss per share was RMB 0.75, improved from RMB 3.366 in the previous year[13]. Dividend and Shareholder Information - The company did not recommend the payment of any dividend for the nine months ended September 30, 2019[6]. - The company does not recommend the payment of an interim dividend for the nine months ended September 30, 2019[14]. - As of September 30, 2019, Ms. Sun Li holds 300,000,000 shares, representing 15.83% of the issued share capital[23]. - Major shareholders include Tianjin TEDA International Entrepreneurship Center with 182,500,000 shares (9.63%) and Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%)[28]. - The company has not approved any new share option plans during the review period ending September 30, 2019[34]. - The company has not repurchased any of its shares during the review period[36]. Operational Insights - The company is involved in two main business areas: bio-composite fertilizers and healthcare services, focusing on elderly care and management[16]. - The company emphasizes the importance of compound fertilizers in agricultural production, which remains a significant industry affecting national livelihood[22]. - The company plans to optimize its internal organizational structure and reduce production costs to ensure stable development of its compound fertilizer business[22]. - The healthcare and elderly care industry is identified as a sunrise industry, with the company focusing on innovation and resource optimization to create new profit growth points[22]. - The company is actively seeking suitable properties and partners to expand its elderly care market[22]. - The company has initiated collaborations with private medical institutions for brainwave detection services and plans to continue diversifying its business model[22]. Governance and Compliance - The company has adhered to all provisions of the Corporate Governance Code except for A.2.1, which requires the roles of Chairman and CEO to be separate[38]. - From February 1, 2019, the company has complied with all other provisions of the Corporate Governance Code following the appointment of Mr. Yang as the new CEO[39]. - The audit committee has reviewed the group's performance for the nine months ending September 30, 2019[33]. Accounting Standards - The group adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2011, which did not have a significant impact on its unaudited operating results and financial position[8]. - The company continues to operate under the assumption of going concern, dependent on its future operational success[8]. Cost Management - The sales and distribution costs decreased by 20.00% to RMB 13,472,729 from RMB 16,839,040 in the previous year[18]. - Research and development and administrative expenses were RMB 29,011,540, a reduction of 10.80% compared to RMB 32,525,176 in 2018[18]. - Financing costs increased significantly by 588.76% to RMB 2,494,206 from RMB 362,130 in the previous year[18].

法 天 津 泰 建 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其他在本交易所上市的公司帶有較高投資風險的公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考 慮後方作出投資決定。GEM的較高風險及其它特色表示GEM較適合專業及其它老練投資 者。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有 ...

法 天 津 泰 建 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳 的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關 天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本報告的 ...

天 津 泰 達 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189） 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的市場。有意投資 的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險，同 時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關天津泰達生物醫學工程股份 有限公司（「本公司」）的資料；本公司董事願就本報告的資料共同及個別地承擔全部責任。本公司各董事在作 ...